Leading 8 Scary ABT-263 Evidence

Bleeding events were treated with blood product transfusions. The patient with thrombosis and HIT was treated with argatroban followed by warfarin when the platelets normalized. Conclusions: Dabigatran should be used cautiously in older patients with renal insufficiency. Dabigatran should also not be used as a primary treatment in HIT. An international registry should be created to minimize risks of serious adverse events. Other Bleeding Disorders Angiodysplasia constitutes a major cause of lower gastrointestinal (GI) bleeding in patients older than 60 years. This is especially problematic in patients with underlying http://www.selleck.cn/products/Erlotinib-Hydrochloride.html inherited bleeding disorders. Many patients are seen in hematology clinics who have thus become transfusion dependent. In recent years, many modalities have been used with variable results, including octreotide, hormonal agents, and local treatment with argon laser plasma photocoagulation. The presence of lesions at multiple and often inaccessible sites and their recurrence after local therapy render the latter http://www.selleckchem.com/products/MK-2206.html technique frequently impossible or unfavorable. Recently, the antiangiogenic agent, thalidomide and its analogs have emerged as a promising option. We are reporting two patients with significant GI angiodysplasia with repeated blood loss who became heavily transfusion dependent. The first patient had multiple comorbidities including congestive heart failure, severe hypertension, and chronic kidney disease. Over a period of 2 years, she received transfusion of more than 100 units of packed red blood cells. The second patient had Von Willebrand (vW) disease Type 3, with sporadic episodes of GI bleeding over the preceding 5�C10 years, that became more frequent and severe, requiring frequent hospitalizations. Endoscopy confirmed the http://www.selleckchem.com/products/ABT-263.html presence of significant angiodysplasia in the stomach and small intestine in both patients. Both were treated with thalidomide and within a few days to weeks of treatment became transfusion free. Medication was well tolerated in both instances. The first patient stopped taking the medicine after ?2 months and started having recurrent bleeding, and treatment was resumed with successful control. Conclusion: We describe the successful use of thalidomide in two patients with chronic GI bleeding due to angiodysplasia who were transfusion dependent. Although there have been multiple reports of thalidomide's successful use for this indication in recent years, studies are needed to assess the long-term success and effects. Severe factor X-deficient patient (Factor X